IRCCS
Institut de
Recherche Clinique
sur les cancers et le sang
The IRCCS association acts as a driving force of progress in health, by providing the hematology department of Lyon Sud Hospital with a clinical research support structure encompassing all the necessary players.
417
Participating patients in 2025
25
People dedicated to hematology research
91.4%
satisfaction of our partners
Photo credits: Olivier Ramonteu
EXPERTISE
A European reference center in clinical research
A large network of patients
In 2025, 417 patients participated in a hematology clinical trial thanks to our structure, including 101 in early phase trials. Clinical studies are carried out in both myeloid and lymphoid hematology fields.
A center at the forefront of innovation
The treatments or treatment regimens evaluated today in clinical trials are the therapeutic strategies of tomorrow. Our center is at the forefront of medical innovation by offering our patients trials of new therapies, such as CAR-T cells or combined approaches limiting conventional chemotherapy.
More than 20 years of experience
Founded in 2000, IRCCS operational structure has become a major partner in clinical research in hematology, recognized as a third-party structure by the Hospices Civils de Lyon (HCL).
IRCCS stands out for its role as an intermediary between the different stakeholders (researchers, clinicians, patients, funders) and for its ethical and innovative commitment.
Latest publications
Find the latest news from IRCCS
Clinical trials
Published on 10/01/2026
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Matthew J Maurer, Vit K Prochazka, Tarec Christoffer El-Galaly, Christopher R Flowers, Diego Villa, Emmanuel Bachy, Elliot J Cahn, Marguerite Fournier, Melissa C Larson, Caroline E Dietrich, Lasse Hjort Jakobsen, Hervé Ghesquières, Robert Kridel, Maher K Gandhi, Chan Y Cheah, Eliza A Hawkes, John F Seymour, Ciara L Freeman, Michael R Clausen, Björn E Wahlin, Jonathan W Friedberg, Carla Casulo, Thomas M Habermann, Yucai Wang, Loretta J Nastoupil, Peter de Nully Brown, David Belada, Andrea Janíková, Heidi Mocikova, Tomáš Fürst, Pierre Feugier, Hervé Tilly, Corinne Haioun, Andrew J Davies, Guillaume Cartron, Richard Burack, Dai Chihara, Peter Martin, Jonathon B Cohen, Izidore S Lossos, Brad S Kahl, Laurie H Sehn, Karin E Smedby, Gilles Salles, Marek Trneny, Brian K Link, Franck Morschhauser, James R Cerhan
Read more
Clinical trials
Studies on data
Published on 09/01/2026
Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy
Hervé Ghesquières, Youenn Drouet, Susan L Slager, Franck Morschhauser, Edith Julia, Sara Galimberti, Dennis Robinson, Melissa C Larson, Quentin Testard, Bruno Tesson, Jean-François Deleuze, Anne Boland, Emilie Thomas, Christine Lasset, Anne J Novak, Luc Xerri, Stefano Luminari, Aurelie Verney, Camille Laurent, Lisa M Rimsza, Thomas M Habermann, Massimo Federico, Brian K Link, Gilles Salles, James R Cerhan
Read more
Events
Published on 04/11/2025
SAVE THE DATE Post-regional ASH: March 6, 2026
Provisional program, subject to change:
9:00 AM: Welcome of participants: Prof. Bachy, Dr. Golfier
9:15 AM: Updates in allogeneic transplantation: Dr. Labussière, Prof. Bay, Dr. Cornillon
9:45 AM: Updates in AML and ALL: Dr. Heiblig, Dr. Carre, Dr. Balsat
Coffee break
11:15 AM: Updates in myelodysplastic syndromes: Dr. Fossard, Prof. Park
11:45 AM: Updates in lymphomas: Prof. Ghesquieres, Dr. Carras, Dr. Sesques, Dr. Fouillet
Lunch break
2:00 PM: Updates in benign hematology: Prof. Garban
2:15 PM: Updates in PNH, aplasias, and myeloproliferative syndromes: Dr. Alcazer, Dr. Barraco
3:15 PM: Updates in multiple myeloma: Dr. Karlin, DR. Lazareth, DR. Chalayer
Coffee Break
3:45 PM: News in the LLC: Prof. Guiez, Dr. Ferrant
4:15 PM: Conclusions and Acknowledgments: Prof. Bachy
Join us
Join clinical research
Clinical research is one of the missions of the hematology department of Lyon Sud Hospital. It is ensured at the operational level by the IRCCS structure marked by:
Innovation
Our partners (academic or industrial societies) trust us to provide our patients with innovative therapies such as CAR-T cells or “first in Human” trials.
Multidisciplinary teamwork
The structure is entirely dedicated to clinical research. It manages all aspects of studies, namely all administrative procedures from the opening to the closing of the trials, but also treatment and monitoring of patients. All stakeholders share the desire to further research together with medical teams.
Professional development and expertise
- Work in a constantly evolving field, allowing you to broaden your technical and scientific skills
- Benefit from continuing training through collaboration with multidisciplinary experts and participation in scientific conferences or congresses
The main mission of IRCCS is the organization and management of therapeutic or non-interventional studies of hematological cancers and blood diseases, including participation in national and international multicenter studies.
A dedicated team of 25 clinical research professionals works within this structure integrated into the clinical hematology department of the Hospices Civils de Lyon at Lyon Sud Hospital.
Research needs you
Make a donation
If you wish to support any action of general interest related to blood diseases:
